Kolexia
Gamelin Erick Oncologie médicale
Gamelin Erick
Oncologie médicale
Ico - Site Paul Papin
Angers, France
40 Activités
564 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Déficit en dihydropyrimidine déshydrogénase Adénocarcinome Tumeurs du côlon Métastase tumorale Tumeurs du rectum Carcinomes Tumeurs du foie Maladies de la peau

Collaborateurs

Voir plus
Boisdron Michele
Boisdron Michele
Ico - Site Paul Papin, Angers, France
Capitain Olivier
Capitain Olivier
Ico - Site Paul Papin, Angers, France
Metges Jean-Philippe
Metges Jean-Philippe
Hôpital Morvan, Brest, France
Faroux Roger
Faroux Roger
Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer: A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
Essai Clinique (Amgen)   06 novembre 2019
Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method
ESMO 20th World Congress on Gastrointestinal Cancer 20–23 June 2018, Barcelona, Spain   01 juin 2018
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.
Annals of oncology : official journal of the European Society for Medical Oncology   29 janvier 2018
In reply.
Seminars in oncology   04 août 2017
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.
Clinical pharmacology and therapeutics   09 juin 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Seminars in oncology   11 février 2017
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
Seminars in oncology   09 février 2017
Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1.
Oncotarget   19 janvier 2016
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Pharmacogenomics   30 novembre 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas ( ).
Oncologie (Paris, France)   21 décembre 2014